Milciclib Maleate

DB16232InvestigationalSmall molecule

Milciclib Maleate is under investigation in clinical trial NCT01301391 (Study of Oral PHA-848125AC in Patients With Malignant Thymoma Previously Treated With Multiple Lines of Chemotherapy).

Mechanism: Pharmacologically active on High affinity nerve growth factor receptor, Cyclin-dependent kinase 2, and Cyclin-dependent kinase 1
Curator reviewed
Formula / weight: C₂₅H₃₂N₈O · 460.586 g/mol (avg)
Also known as: Milciclib
Code names: PHA-848125

Resolves to

Compound

UNII688000M8S8CAS802539-81-7ChEMBLCHEMBL564829

Structure

InChIKeyRXZMYLDMFYNEIM-UHFFFAOYSA-NSMILESCNC(=O)C1=NN(C)C2=C1C(C)(C)CC1=C2N=C(NC2=CC=C(C=C2)N2CCN(C)CC2)N=C1

Targets

P04629NTRK1P24941CDK2P06493CDK1P11802CDK4

What you can answer from here — as of June 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

15+ReferencesStructured and connected to the statements they support

Which drugs share a target with Milciclib Maleate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account